Dr. Paik Discusses Advances in Squamous Cell Lung Cancer

Paul K. Paik, MD
Published: Friday, Jan 05, 2018



Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent advancements in squamous cell lung cancer.

The biggest recent advancement in the treatment of squamous cell lung cancer is immunotherapy, says Paik. In 2015, the CheckMate-017 trial led to the first approval of immunotherapy in lung cancer.

In the wake of immunotherapy, excitement for chemotherapy options has lessened, adds Paik.
 


Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent advancements in squamous cell lung cancer.

The biggest recent advancement in the treatment of squamous cell lung cancer is immunotherapy, says Paik. In 2015, the CheckMate-017 trial led to the first approval of immunotherapy in lung cancer.

In the wake of immunotherapy, excitement for chemotherapy options has lessened, adds Paik.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Publication Bottom Border
Border Publication
x